Genentech: Phase III study of the combination of tiragolumab in advanced lung cancer does not meet its main objective

SOUTH SAN FRANCISCO (dpa-AFX) – Genentech announced that the Phase III SKYSCRAPER-01 study, which evaluated tiragolumab in combination with Tecentriq (atezolizumab) versus Tecentriq alone in patients with PD-L1-high, locally advanced or metastatic non- small cell lung cancer, did not meet the primary endpoint of overall survival in the final analysis. The observed overall safety profile remained consistent over longer follow-up, and no new safety signals were identified.

Genentech, a member of the Roche Group (RHHBY), noted that it is continuously assessing its study programs to determine if adjustments are needed in light of ongoing research. The company will apply the same principles to this program, with additional data from Phase III studies in different settings or tumor types expected next year.

SKYSCRAPER-01 is a global Phase III, randomized, double-blind study evaluating tiragolumab plus Tecentriq compared to Tecentriq alone in 534 patients with PD-L1-high, previously untreated, locally advanced, unresectable, or metastatic NSCLC. Patients were randomized 1:1 to tiragolumab plus Tecentriq or placebo plus Tecentriq until disease progression, loss of clinical benefit, or unacceptable toxicity.

For more such health news, visit rttnews.com.

Copyright(c) 2024 RTTNews.com. All rights reserved

Copyright RTT News/dpa-AFX